DocWire News Editors

DocwireNews

According to data presented at the 2021 American Society of Hematology Annual Meeting, an updated International Prognosis Scoring System (IPSS) for myelodysplastic syndromes (MDS) that incorporates gene mutations (IPSS-M) led to improved discrimination compared with the revised IPSS (IPSS-R).&nbsp; The IPSS-M, which considers clinical, cytogenetic, and genetic parameters, reclassified nearly half of patients studied.The IPSS-M score was built as a weighted sum of prognostic variables. The model consisted of:<ul>
<li>hemoglobin, platelets, and bone marrow blasts</li>
<li>IPSS-R cytogenetic category</li>
<li>22 binary features derived from the presence of mutations in 21 predictive genes</li>
<li>one feature representing the number of mutations from a group of 17 additional genes</li>
</ul>Investigators applied scaling so that a score of 0 represented an average patient; scores of &ndash;1, 1, or 2 corresponded to half-, double-, or four-fold risk compared with an average patient.Researchers characterized 9,339 driver mutations or short indels involving 124 genes from 2,957 patients (discovery cohort). These patients had less than 20% blasts and white blood cell count below 13&times;109/L. Median follow-up was 3.8 years.They then conducted correlative analyses between genetic alterations and clinical outcomes. Results were validated in an independent cohort of 718 patients.According to the investigators, the IPSS-M resulted in improved discrimination compared with the IPSS-R for leukemia-free survival, overall survival, and leukemic transformation. Specifically, they found a 5-point increase in C-index for each endpoint in the discovery cohort and an increase of 3.4, 1.5, and 4.9 points in the validation cohort.Based on score cutoffs, researchers established a six-risk category schema: very-low (14%), low (32%), moderate-low (11%), moderate-high (11%), high (11%), and very-high (18%). From very-low to very-high, the median leukemia-free survival was 9.7, 6.0, 4.1, 2.3, 1.7, and 0.75 years, respectively.By merging the moderate-low and moderate-high categories to moderate, the researchers compared stratification of the IPSS-R with the IPSS-M. The IPSS-M resulted in restratification of 46% of patients. The majority (74%) were upstaged and 26% were downstaged.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

New IPSS Model Incorporates Genetic Data to Better Risk-Stratify MDS Patients

ASH Annual Meeting and Exposition 2021

According to data presented at the 2021 American Society of Hematology Annual Meeting, an updated International Prognosis Scoring System (IPSS) for myelodysplastic syndromes ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe